Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yaqoob, M.
Right arrow Articles by Ahmad, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yaqoob, M.
Right arrow Articles by Ahmad, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1992) 7: 125-128
© 1992 European Renal Association-European Dialysis and Transplant Association

research-article

Suppression of the renin-angiotensin-aldosterone axis with erythropoietin therapy by a negative feedback loop

M. Yaqoob1,, K. Morris2, G. M. Bell1 and R. Ahmad1

1Departments of Renal Medicine, Royal Liverpool Hospital Liverpool, UK 2Departments of Chemical Pathology, Royal Liverpool Hospital Liverpool, UK

Correspondence and offprint requests to: Correspondence and offprint requests to: Dr M. Yaqoob, Renal Research Fellow, Link Unit 6Z, Royal Liverpool Hospital, Prescot Street, Liverpool L7 8XP, UK.

To investigate the pathophysiology of hypertension in patients receiving recombinant human erythropoietin (rHuEpo) we studied its effects on the renin-aldosterone axis of chronic haemodialysis (HD) patients not receiving antihypertensive drugs. Nine severely anaemic normotensive HD patients received rHuEpo 50 U/kg bodyweight, thrice weekly after each HD. The dose was increased by 25 U/kg bodyweight every 4 weeks to a maximum of 100 U/kg or until an increase of Hb or Hct of 2 g/dl or 7% was achieved. Blood samples were taken after 30 min supine rest and while seated 10 min later after gentle ambulation. Results expressed as mean±SEM:

Both parameters decreased in all patients during rHuEpo therapy, but there were no changes in mean arterial pressure (89 ± 5 versus 89 ± 5 mmHg) or bodyweight (62 ±5 versus 62 ±5 kg). Haemoglobin (g/dl) and haematocrit (%) increased from 6.2 ±0.6 and 19.1 ±0.8 to 8.2±1.3 and 24.5±1.14 respectively (P<0.01). We therefore conclude that suppression of the renin-aldosterone axis occurs during rHuEpotherapy in normotensive HD patients by a negative feedback loop, before the development of hypertension.

Keywords: recombinant human erythropoietin; renin-angiotensin-aldosterone axis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
R. Rosario and M. Epstein
Review: Relationship between Erythropoietin Administration and Alterations of Renin-Angiotensin-Aldosterone
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2006; 7(3): 135 - 138.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.